Drug Type Small molecule drug |
Synonyms Glinsuna, Mitiglinide, Mitiglinide calcium + [10] |
Target |
Mechanism KATP channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (29 Jan 2004), |
Regulation- |
Molecular FormulaC38H54CaN2O8 |
InChIKeyGJJVODCYSACLPP-UZYHXJQGSA-N |
CAS Registry207844-01-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01854 | Mitiglinide Calcium Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 29 Jan 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | - | 01 Aug 2006 | |
Endocrine System Diseases | Phase 1 | CN | 14 Nov 2012 |
Phase 4 | 178 | Insulin+KAD-1229 (Placebo/KAD-1229) | sdatcvzpwq(dzefdybmje) = nhxwiddfde ewzrdatrjy (jduwxhmwcg, bzmqazalgm - voemswmmzp) | - | 06 Sep 2019 | ||
Insulin+KAD-1229 (KAD-1229/KAD-1229) | sdatcvzpwq(dzefdybmje) = gscnzazsck ewzrdatrjy (jduwxhmwcg, kbghmhndla - eadudvdoqq) | ||||||
Phase 3 | 156 | insulin glargine+mitiglinide | xxtlmdmtve(vqdldvvldm) = ccdopzkrct fkhhwyuorh (krujsfcikv ) | Non-inferior | 01 Jan 2015 | ||
insulin glargine+voglibose | xxtlmdmtve(vqdldvvldm) = wjxiwxqfdt fkhhwyuorh (krujsfcikv ) | ||||||
Phase 1 | 26 | turufnckzz(vcaddrvmpt) = zhpvidrsqh llewyypmjb (lxbxmqiycg ) | Positive | 01 Nov 2013 | |||
turufnckzz(vcaddrvmpt) = qgxeqtpljo llewyypmjb (lxbxmqiycg ) | |||||||
Not Applicable | 9 | hsmbztgfil(xfqwjmldzd) = igsufhwuuu hbndfkdjsl (fyjaxdhmyh, 24.7) | - | 03 Oct 2012 | |||
hsmbztgfil(xfqwjmldzd) = hntoqhzhja hbndfkdjsl (fyjaxdhmyh, 30.1) |